Isocitrate dehydrogenase(IDH)is an enzymes involved in a variety of metabolic and epigenetic processes.IDH can be detected in approximately 20％of patients with acute myeloid leukemia(AML),the mutated IDH enzyme acquires new oncogenic enzyme activity and converts α-ketoglutaric acid(α-KG)to the tumor metabolite 2-hydroxyglutaric acid(2-HG),which accumulates at high levels in cells and hinders the function of αKG-dependent enzymes,including epigenetic regulators,resulting in DNA hypermethylation,abnormal gene expression,cell proliferation,and abnormal differentiation,and contributes to leukemia disease progression.IDH mutations have different effects on the prognosis of patients with AML depending on the location of the mutation and other co-occurring genomic abnormalities.This paper will review the latest research progress on the IDH positive AML gene changes,prognosis,and inhibitors.
维普
万方数据